Who Optimizes SG&A Costs Better? Corcept Therapeutics Incorporated or TG Therapeutics, Inc.

Biotech Giants: Who Masters SG&A Efficiency?

__timestampCorcept Therapeutics IncorporatedTG Therapeutics, Inc.
Wednesday, January 1, 20143491600024518692
Thursday, January 1, 20153694900019886580
Friday, January 1, 20164524000012631689
Sunday, January 1, 20176241600021977998
Monday, January 1, 20188128900020759000
Tuesday, January 1, 201910035900020838000
Wednesday, January 1, 2020105326000121812000
Friday, January 1, 2021122356000152137000
Saturday, January 1, 202215284800083231000
Sunday, January 1, 2023184259000122706000
Loading chart...

In pursuit of knowledge

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Corcept Therapeutics Incorporated and TG Therapeutics, Inc. have been navigating this challenge since 2014. Over the years, Corcept has shown a steady increase in SG&A expenses, peaking at approximately $184 million in 2023, a 428% rise from 2014. Meanwhile, TG Therapeutics experienced a more volatile trajectory, with a significant spike in 2021, reaching around $152 million, before dropping to $123 million in 2023. This fluctuation highlights TG Therapeutics' aggressive investment in administrative functions, possibly reflecting strategic shifts or expansion efforts. In contrast, Corcept's consistent growth in expenses suggests a more stable, perhaps conservative, approach. Understanding these trends offers valuable insights into each company's operational strategies and financial priorities, providing a window into their long-term sustainability and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025